Is Kenvue (KVUE) overvalued or fairly valued?

MarketChacha shows Kenvue's valuation in context — a trailing P/E of about 20.4, a forward P/E of about 15.5, a price-to-book of about 3.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Kenvue's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.71×) from reported figures — education, not a rating.

What is Kenvue's revenue?

Kenvue reported revenue of $15.1B for FY2025, with net profit of $1.5B, per official filings.

What is the share price of Kenvue (KVUE)?

Kenvue last traded at $18.80 (-2.1% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

Kenvue

KVUE · NYSE · Consumer Staples · United States

Snapshot

TickerKVUE

ExchangeNYSE

SectorConsumer Staples

IndustryHousehold & Personal Products

CountryUnited States

Employees21,780

HeadquartersSummit, United States

Websitewww.kenvue.com

Filings tracked16

About Kenvue

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Who owns it

Insiders0.1%
Institutions95.9%
Public & other4.0%

1,398 institutional holders

Ownership breakdown from public market data.

Top holders

FMR, LLC8.18%
Blackrock Inc.7.85%
Vanguard Capital Management LLC6.52%
State Street Corporation6.33%
Vanguard Portfolio Management LLC4.86%
Pentwater Capital Management Lp2.71%
Geode Capital Management, LLC2.71%
Independent Franchise Partners, LLP2.63%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.71×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend10.8% → 9.7%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev -1% · PAT -6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.9B · EPS 0.27

Est. earnings growth -1.0%

Next fiscal year

Rev $16.0B · EPS 1.24

Est. earnings growth +4.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$15.1B

Net margin

9.7%

ROE

13.7%

Revenue CAGR (2y)

-1.0%

Profit CAGR (2y)

-6.0%

EPS (FY2025)

0.76

Net profit (FY2025)

$1.5B

Ask MarketChacha about KVUE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$15.1B	$1.5B	0.76	9.7%	13.7%
FY2024	$15.5B	$1.0B	0.54	6.7%	10.7%
FY2023	$15.4B	$1.7B	0.90	10.8%	8.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$4.0B	$456.0M	0.24	11.5%
2026Q1	$3.9B	$474.0M	0.25	12.1%
2025Q3	$3.8B	$398.0M	0.21	10.6%
2025Q2	$3.8B	$420.0M	0.22	10.9%
2025Q1	$3.7B	$322.0M	0.17	8.6%
2024Q3	$3.9B	$383.0M	0.20	9.8%
2024Q2	$4.0B	$58.0M	0.03	1.5%
2024Q1	$3.9B	$296.0M	0.15	7.6%
2023Q4	$3.9B	$438.0M	0.23	11.2%
2023Q3	$4.0B	$430.0M	0.23	10.7%
2023Q2	$3.9B	$469.0M	0.27	12.2%
2023Q1	$3.8B	$361.0M	0.21	9.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Shareholder vote results
SEC5/22/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Executive/director change, Exhibits
SEC4/15/2026material
10-K filing
SEC2/20/2026
8-K — Results of operations, Costs from exit/disposal, Exhibits
SEC2/17/2026material
8-K — Executive/director change
SEC2/12/2026material
8-K — Shareholder vote results, Reg FD disclosure, Exhibits
SEC1/29/2026material
8-K — Other events
SEC1/16/2026material

2025

8-K — Results of operations, Exhibits
SEC11/3/2025material
8-K — Material agreement, Executive/director change, Reg FD disclosure, Exhibits
SEC11/3/2025material
10-Q filing
SEC11/3/2025
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.